Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kalaris TherapeuticsKLRS +0.76%12 EBITDA per Share is $-2.14 as of Mar. 2026. GuruFocus rates KLRS with a GF Score™ of 12/100. Among 1,131 Biotechnology companies, Kalaris Therapeutics ranks better than 76.48% on this metric.
Kalaris Therapeutics's EBITDA per Share for the
three
months ended in Mar. 2026 was $-0.46.
Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.14.
During the past 3 years, the average EBITDA per Share Growth Rate was 37.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.
The historical rank and industry rank for Kalaris Therapeutics's EBITDA per Share or its related term are showing as below:
KLRS'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 37.9 Med: 37.9 Max: 37.9
Current: 37.9
During the past 4 years, the highest 3-Year average EBITDA per Share Growth Rate of Kalaris Therapeutics was 37.90% per year. The lowest was 37.90% per year. And the median was 37.90% per year.
KLRS's 3-Year EBITDA Growth Rate is ranked better than 76.48% of 1131
companies
in the Biotechnology industry
Industry Median: 14.9
vs KLRS: 37.90
During the past 3 years, the average EBITDA Growth Rate was -40.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.
During the past 4 years, the highest 3-Year average EBITDA Growth Rate of Kalaris Therapeutics was -40.20% per year. The lowest was -40.20% per year. And the median was -40.20% per year.
Kalaris Therapeutics (NAS:KLRS) EBITDA per Share Explanation
EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.
While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.
The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.
EBITDA can be thought of as the cash a business generates that is available to:
Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners
EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.
A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.
Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.
Be Aware
Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.
EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.
Kalaris Therapeutics EBITDA per Share Related Terms
Kalaris Therapeutics EBITDA per Share Historical Data
* Premium members only.
The historical data trend for Kalaris Therapeutics's EBITDA per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Kalaris Therapeutics's EBITDA per Share for the fiscal year that ended in Dec. 2025 is calculated as
EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kalaris Therapeutics (KLRS) has a EBITDA per Share of $-2.14 as of Mar. 2026. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Kalaris Therapeutics and its competitors. According to the industry distribution chart, Kalaris Therapeutics ranks #266 out of 1131 companies in the Biotechnology industry, placing it in the top 23.5%.
Is Kalaris Therapeutics' EBITDA per Share too high?
Kalaris Therapeutics' current EBITDA per Share is $-2.14. Based on the distribution chart, Kalaris Therapeutics ranks #266 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kalaris Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kalaris Therapeutics' EBITDA per Share compare to HRTX and VRCA?
According to the Biotechnology industry distribution chart, Kalaris Therapeutics ranks #266 out of 1131 companies for EBITDA per Share. This places Kalaris Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median EBITDA per Share is 14.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Biotechnology company?
The median EBITDA per Share among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Kalaris Therapeutics and its competitors. For the Biotechnology industry, the median EBITDA per Share is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kalaris Therapeutics's current EBITDA per Share is $-2.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kalaris Therapeutics stock overvalued right now?
Kalaris Therapeutics (KLRS) has a current EBITDA per Share of $-2.14. The current EBITDA per Share is $-2.14. Kalaris Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Kalaris Therapeutics (KLRS), the current EBITDA per Share is $-2.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
12GF Score
Get the complete analysis for KLRS
EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KLRS has been successfully added to your 
